Seth Klarman's Baupost Group sold all its shares in Vaxcyte and Willis Towers Watson during Q2 2026, exiting positions it had only recently established. The move reflects a quick change in risk appetite, especially for Vaxcyte, a clinical-stage biotech with no product revenue and a key vaccine trial data expected in Q4 2026. Baupost's exit suggests the trade was opportunistic rather than a long-term hold. Retail investors should note 13F filings lag by about 45 days, so following such moves without timing awareness can lead to missed exits. Investors interested in Vaxcyte should be prepared to hold through upcoming trial results in late 2026 and early 2027.
The Toro Company reported strong third-quarter results with net sales up 8.4% to $1.23 billion and adjusted EPS of $1.33, beating estimates. Operational efficiency improved, pushing the adjusted operating margin to 13.9%, driven by productivity gains...
KNOT Offshore Partners LP reported strong Q2 2026 results, beating analyst expectations with an EPS of $0.10 versus an estimated loss of $0.03 and revenue of $96.78 million exceeding forecasts. The company maintained a high shuttle tanker fleet utili...
Alphabet CEO Sundar Pichai told employees that Waymo, the company's self-driving car unit, could start making a meaningful financial contribution as soon as 2027. This suggests that Alphabet's investment in autonomous driving technology may be closer...
Mama's Creations reported a strong Q2 fiscal 2027 with revenue up 55% to $54.6 million and net income doubling to $2.6 million. The company’s growth is driven by new product launches, effective cross-selling, and inclusion in Costco's national mailer...
GoodRx has introduced the Companion Family Plan, a subscription service covering a primary member plus up to four dependents, including children, adults, and pets. The plan offers free generic medications, discounted drugs under $10, and savings on d...
